中国免疫学杂志
中國免疫學雜誌
중국면역학잡지
CHINESE JOURNAL OF IMMUNOLOGY
2014年
12期
1611-1615
,共5页
崔澂%郝淑维%刘杰%郑文广%王雅卓%张斯斯%阎娟%吕微%李梅香
崔澂%郝淑維%劉傑%鄭文廣%王雅卓%張斯斯%閻娟%呂微%李梅香
최징%학숙유%류걸%정문엄%왕아탁%장사사%염연%려미%리매향
T淋巴细胞%Exosomes%过继转输%妊娠丢失%胚胎发育%小鼠
T淋巴細胞%Exosomes%過繼轉輸%妊娠丟失%胚胎髮育%小鼠
T림파세포%Exosomes%과계전수%임신주실%배태발육%소서
Tlymphocytes%Exosomes%Adoptive transferring%Pregnancy loss%Fetation%Mice
目的:分析雄性T淋巴细胞及其Exosomes(Exo)过继转输对妊娠丢失孕鼠胚胎发育的保护作用。方法:分别将健康男性外周血单个核细胞( PBMC)、BALB/c及DBA/2雄鼠脾细胞体外诱导增殖,蔗糖密度梯度离心联合超滤制备Exo。CBA/J(♀)×BALB/c(♂)为正常妊娠对照,CBA/J(♀)×DBA/2(♂)为妊娠丢失URSA模型。将URSA孕鼠随机分组,经尾静脉或皮下注射,分别予以父方、非父方、无关雄鼠脾细胞或其Exo,以及男性PBMC来源Exo过继转输。观察胚胎发育,计算胎盘体积、胚胎吸收率及妊娠丢失率。结果:URSA组胎盘体积明显缩小,胚胎吸收率、妊娠丢失率显著升高(均P<0.0005);尾静脉或皮下注射不同来源细胞及Exo后,孕鼠胎盘体积显著恢复,胚胎吸收率、妊娠丢失率显著下降(均P<0.0005)。不同治疗组内两种注射途径产生的疗效无差异(均P>0.05);不同细胞来源Exo过继转输后,胚胎吸收率的下降幅度显著强于细胞治疗组(均P<0.05);男性Exo过继转输后,妊娠丢失率的下降幅度显著强于细胞治疗组及鼠源Exo治疗组(均P<0.05)。结论:过继转输不同来源雄性T淋巴细胞及其Exo均可明显改善胚胎发育。 Exo作为非细胞成分生物学制剂,有望取代传统细胞过继免疫治疗。
目的:分析雄性T淋巴細胞及其Exosomes(Exo)過繼轉輸對妊娠丟失孕鼠胚胎髮育的保護作用。方法:分彆將健康男性外週血單箇覈細胞( PBMC)、BALB/c及DBA/2雄鼠脾細胞體外誘導增殖,蔗糖密度梯度離心聯閤超濾製備Exo。CBA/J(♀)×BALB/c(♂)為正常妊娠對照,CBA/J(♀)×DBA/2(♂)為妊娠丟失URSA模型。將URSA孕鼠隨機分組,經尾靜脈或皮下註射,分彆予以父方、非父方、無關雄鼠脾細胞或其Exo,以及男性PBMC來源Exo過繼轉輸。觀察胚胎髮育,計算胎盤體積、胚胎吸收率及妊娠丟失率。結果:URSA組胎盤體積明顯縮小,胚胎吸收率、妊娠丟失率顯著升高(均P<0.0005);尾靜脈或皮下註射不同來源細胞及Exo後,孕鼠胎盤體積顯著恢複,胚胎吸收率、妊娠丟失率顯著下降(均P<0.0005)。不同治療組內兩種註射途徑產生的療效無差異(均P>0.05);不同細胞來源Exo過繼轉輸後,胚胎吸收率的下降幅度顯著彊于細胞治療組(均P<0.05);男性Exo過繼轉輸後,妊娠丟失率的下降幅度顯著彊于細胞治療組及鼠源Exo治療組(均P<0.05)。結論:過繼轉輸不同來源雄性T淋巴細胞及其Exo均可明顯改善胚胎髮育。 Exo作為非細胞成分生物學製劑,有望取代傳統細胞過繼免疫治療。
목적:분석웅성T림파세포급기Exosomes(Exo)과계전수대임신주실잉서배태발육적보호작용。방법:분별장건강남성외주혈단개핵세포( PBMC)、BALB/c급DBA/2웅서비세포체외유도증식,자당밀도제도리심연합초려제비Exo。CBA/J(♀)×BALB/c(♂)위정상임신대조,CBA/J(♀)×DBA/2(♂)위임신주실URSA모형。장URSA잉서수궤분조,경미정맥혹피하주사,분별여이부방、비부방、무관웅서비세포혹기Exo,이급남성PBMC래원Exo과계전수。관찰배태발육,계산태반체적、배태흡수솔급임신주실솔。결과:URSA조태반체적명현축소,배태흡수솔、임신주실솔현저승고(균P<0.0005);미정맥혹피하주사불동래원세포급Exo후,잉서태반체적현저회복,배태흡수솔、임신주실솔현저하강(균P<0.0005)。불동치료조내량충주사도경산생적료효무차이(균P>0.05);불동세포래원Exo과계전수후,배태흡수솔적하강폭도현저강우세포치료조(균P<0.05);남성Exo과계전수후,임신주실솔적하강폭도현저강우세포치료조급서원Exo치료조(균P<0.05)。결론:과계전수불동래원웅성T림파세포급기Exo균가명현개선배태발육。 Exo작위비세포성분생물학제제,유망취대전통세포과계면역치료。
Objective:To analyze the protective effects of adoptively transferring different patrilineal lymphocytes and their Exosomes ( Exo) on fetation of mice with pregnancy loss comparatively.Methods: The peripheral blood mononuclear cells ( PBMC) from healthy men and the splenocytes from BALB/c and DBA/2 male mice were induced in vitro ,and their Exo were isolated through sucrose gradient ultra-centrifugation combined with ultrafiltration.The mice of CBA/J (♀) mated with BALB/c (♂) were enrolled as control group of normal pregnancy ,and the CBA/J (♀) mated with DBA/2 (♂) as URSA of pregnancy loss experimental animal model.The mice in URSA group were randomly divided into each group with treatment through adoptively transferring , which were injected intravenously or subcutaneously with splenocytes or splenocytes -derived Exo from mated DBA/2,unmated DBA/2 or unrelated BALB/c,also PBMC-derived Exo from men,respectively.And then,the placenta volumes,rates of fetal absorption and pregnancy loss were calculated to observe the fetation of embryos.Results:Compared with the group of normal pregnancy ,the placenta volumes from URSA group decreased greatly ,and rates of fetal absorption and pregnancy loss elevated greatly ( all P<0.000 5 ).After transferring different sources of cells and their Exo through different injection ,the placenta volumes resumed to the level of normal pregnancy ,and the rates of fetal absorption and pregnancy loss decreased significantly ( all P<0.000 5 ).No differences were observed after treatment through injecting intravenously or subcutaneously ( all P>0.05 ).After transferring the Exo derived from either male mice or healthy men,the level of decreased fetal absorption rates were more than that in cellular-therapy groups ( all P<0.05 ).After transferring the Exo derived from men ,the level of decreased pregnancy loss rates were more than that in cellular -therapy groups and mice splenocytes-derived Exo group ( all P<0.05 ).Conclusion:Adoptively transferring patrilineal T lymphocytes and their Exo can greatly improve the fetation.Exo should become a non-cellular bio-remedy,which is expected to replace traditional immunotherapy of adoptively transferring lymphocytes.